KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Payables: 2009-2024

Historic Payables for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $789.5 million.

  • Regeneron Pharmaceuticals' Payables rose 81.74% to $903.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 33.63%. This contributed to the annual value of $789.5 million for FY2024, which is 30.15% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Payables of $789.5 million as of FY2024, which was up 30.15% from $606.6 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Payables ranged from a high of $789.5 million in FY2024 and a low of $475.5 million during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' Payables had a median value of $606.6 million in 2023 and averaged $661.8 million.
  • Data for Regeneron Pharmaceuticals' Payables shows a peak YoY spiked of 30.15% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Payables stood at $475.5 million in 2020, then climbed by 18.61% to $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then soared by 30.15% to $789.5 million in 2024.